Myriad

2 known investors

Myriad provides germline and tumor genomic testing across hereditary cancer, prenatal and reproductive health, prostate cancer, and pharmacogenomics for mental health medications. It supplies patients and healthcare providers with genetic screening results and AI-derived insights to inform diagnosis, risk assessment, and treatment decisions.